Innate Pharma (IPHA) SEC Filings & 10K Form

$2.91
+0.20 (+7.38%)
(As of 10:14 AM ET)

Recent Innate Pharma SEC Filings

DateFilerForm TypeView
05/15/2024
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2024
5:07 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2024
5:03 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024
5:02 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
5:51 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/04/2024
7:03 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/21/2024
8:20 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/21/2024
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/19/2024
5:33 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/14/2024
6:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/21/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2024
4:00 PM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 424B5
02/06/2024
4:05 PM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/16/2024
11:15 PM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form EFFECT
01/12/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/05/2024
5:09 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/04/2024
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/04/2024
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2023
3:45 PM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
12/20/2023
3:30 PM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/19/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/18/2023
10:40 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/11/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/11/2023
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/27/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/07/2023
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/27/2023
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/19/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/10/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/05/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/14/2023
5:27 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/14/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/29/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/10/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry
07/11/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2023
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/16/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2023
5:01 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/08/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2023
5:00 AM
Innate Pharma SA (Filer)
Innate Pharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:IPHA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners